developing innovative diagnostics and therapies.
Cerelux, LLC’s mission is to improve the prognosis of stroke patients by developing innovative diagnostics and therapies.
Stroke is a very heterogeneous disease and ischemic stroke affects over 700,000 patients every year in the US. Emergent large vessel occlusion (ELVO) is a leading cause of death and disability each year throughout the world, accounting for 30-40% of all ischemic stroke, which equates to around 276,000 patients in the U.S. each year. Stroke also leads to vascular cognitive impairment and dementia (VCID), which occurs in 25-30% of stroke patients. Intravenous t-PA and mechanical thrombectomy (MT, endovascular removal of the thrombus using suction and/or stent-retriever devices) have greatly improved the ability to restore blood flow during a stroke; indeed, thrombectomy improves patient outcomes even if initiated 24 hours after stroke onset. Despite these effective strategies to re-establish blood flow, patients still have significant long-term functional and cognitive deficits, only 17% of patients achieved a normal outcome without any disability. Pre-procedure imaging and successful procedure completion are not reliable to predict patient prognosis and new approaches are needed to predict and improve patient prognosis.
Cerelux, LLC is discovering in-vitro diagnostics and adjuvant therapies by investigating the cellular/molecular events occurring during a stroke in the vicinity of the infarct by accessing samples from stroke patients during mechanical thrombectomy procedures.